10-Q: InspireMD Reports Q1 2025 Results: Revenue Stable, Losses Widen Amid U.S. Expansion Efforts

InspireMD's Q1 2025 results show stable revenue but increased net losses due to higher operating expenses related to U.S. expansion and R&D investments.

Summary

• InspireMD, Inc. reported its financial results for the first quarter of 2025.
• Revenue remained relatively stable at $1.529 million compared to $1.511 million in Q1 2024.
• However, the company's net loss increased significantly to $11.166 million, compared to $7.032 million in the same period last year.
• This increase in net loss was primarily driven by higher operating expenses, particularly in research and development, and selling and marketing.
• The company's cash and cash equivalents decreased from $18.916 million at the end of 2024 to $12.383 million as of March 31, 2025.
• Marketable securities also decreased from $15.721 million to $13.703 million over the same period.
• InspireMD is seeking FDA approval for its CGuard Prime carotid stent system, with potential approval expected in the third quarter of 2025.
• The company has expressed substantial doubt about its ability to continue as a going concern without additional funding.
• Management plans include continued commercialization and raising capital through equity, debt, or strategic partnerships.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue is stable and there's progress on regulatory approvals, the widening losses, decreasing cash reserves, and going concern warning weigh heavily on the sentiment.

Positives

• Revenue remained relatively stable compared to the same period last year.
• The company is progressing towards potential FDA approval for its CGuard Prime carotid stent system.
• Positive one-year follow up results from the C-GUARDIANS trial were announced in May 2024.
• The Centers for Medicare and Medicaid Service (CMS) expanded coverage for both CAS and TCAR to include both asymptomatic and standard risk patients.

Negatives

• The company's net loss increased significantly due to higher operating expenses.
• Cash and cash equivalents have decreased substantially.
• The company has expressed substantial doubt about its ability to continue as a going concern.
• The company is still reliant on raising additional capital to fund operations.

Risks

• The company's history of recurring losses and negative cash flows raises concerns about its ability to continue as a going concern.
• The company's ability to secure and maintain regulatory approvals for its products is crucial.
• Intense competition in the medical device industry could impact market acceptance of the company's products.
• Political and economic instability in Israel, where the company's manufacturing facility is located, could disrupt operations.
• Changes to trade policy, including tariff and customs regulations, or failure to comply with such regulations may have an adverse effect on our reputation, business, financial condition and results of operations.

Future Outlook

The company anticipates potential FDA approval for its CGuard Prime carotid stent system in the third quarter of 2025 and plans to continue commercialization efforts and raise capital through various means.

Management Comments

• Growth in the quarter was driven by continued adoption of our CGuard technology, offset by the impact of foreign exchange and distributors managing CGuard inventory levels in anticipation of the potential CGuard Prime approval in Europe.
• We continue to invest in current and future potential new indications, products and manufacturing enhancements for CGuard that are expected to reduce cost of goods and/or provide the best-in-class performing delivery systems, such as CGuard Prime.

Industry Context

InspireMD operates in the competitive medical device industry, specifically focusing on carotid artery disease treatment. The company's efforts to gain FDA approval for CGuard Prime and expand its product line align with the broader industry trend of developing less invasive and more effective treatments for vascular diseases. The expansion of CMS coverage for CAS and TCAR procedures also creates a more favorable market environment for InspireMD's products.

Comparison to Industry Standards

• The document mentions that the primary endpoint in the C-GUARDIANS trial was compared to a performance goal based on the observed rate of the two components of the primary endpoint from previous pivotal stent trials which are considered industry standard.
• The performance goal was considered met if the upper bound of the two-sided 95% confidence interval calculated from the observed primary endpoint rate is < 11.6% and the p-value is less than 0.025.
• The company announced positive 30-day follow up results from the C-GUARDIANS trial in which stenting with the CGuard Carotid Stent System in patients with carotid artery stenosis and at high risk for carotid endarterectomy had a DSMI rate of 0.95%, measured from the date of the procedure through 30 days follow-up post-procedure.
• In May 2024, the company announced positive one-year follow up results from the C-GUARDIANS trial, with a rate of 30-day DSMI and ipsilateral stroke between 31 and 365 days of 1.95%.

Management Changes

Related Party Transactions

• During the three months ended March 31, 2025 and 2024, a member of the immediate family of the CEO provided certain administrative services in connection with the Companys expansion to the U.S. in the amount of $ 24 thousand and $ 15 thousand, respectively.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures or restructuring if the company fails to secure additional funding.
• Customers and patients could benefit from the potential approval and commercialization of CGuard Prime.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• Continue commercialization of existing products.
• Pursue FDA approval for CGuard Prime.
• Advance development of SwitchGuard NPS.
• Explore new indications for CGuard.
• Raise additional capital through equity, debt, or strategic partnerships.

Key Dates

Keywords

CGuard Prime, carotid stent, InspireMD, financial results, medical device, net loss, revenue, FDA approval, going concern, Q1 2025